Date: 2018-08-24
Type of
information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in Stem Cell Research and Therapy
Company: Exocobio (Republic of Korea)
Product: stem cell-derived exosomes
Action
mechanism: exosome
Disease: atopic dermatitis
Therapeutic
area: Autoimmune diseases - Dermatological diseases
Country:
Trial
details:
Latest
news:
- • On August 24, 2018, ExoCoBio announced that the company published a scientific paper in Stem Cell Research and Therapy. This paper indicates that stem cell-derived exosomes dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets. According to the paper, the symptoms of mice having severe atopic dermatitis were significantly improved after administration of stem cell-derived exosomes intravenously or subcutaneously, so that the level of serum immunoglobulin E (IgE), the number of eosinophils in blood, and the number of mast cells in the skin lesion were decreased. It has also been found that the number of inflammatory dendritic epidermal cells (IDECs), which are not found in normal skin but cause an allergic inflammatory response in atopic dermatitis lesions, also significantly decreased to a normal skin level after administration of stem cell-derived exosomes. In addition, the improvement of the symptoms by stem cell-derived exosomes was comparable to that of a steroid drug, prednisolone.
- Exocobio is currently developing a new drug candidate based on stem cell-derived exosomes that can modulate the activity of various immune cells causing dermatitis, with a mechanism that fundamentally inhibits the production of inflammatory cytokines.
Is
general: Yes
